Want to join the conversation?
Generics manufacturer $MYL launches Fluvastin Sodium Extended-release Tablets, 80 mg, in the U.S. for the treatment of patients with hypercholesterolemia and mixed dyslipidemia. The product is the generic equivalent of Novartis' Lescol XL Tablets. Per IMS Health, Lescol generated almost $38MM in U.S. sales in the 12-month period ending June 30.
The latest earnings report by $VZ shows how it is losing customers despite offering the unlimited data plans, a record for the company.
$BEBE is closing down all its stores by the end of May.
$WFC agreed to hike its payout in a class-action settlement over unauthorized accounts by $32 million to $142 million for its retail sales practices. The settlement will now include customers who were impacted as early as May 2002.